Skanor, Sweden

Hans Lilja


Average Co-Inventor Count = 2.8

ph-index = 7

Forward Citations = 143(Granted Patents)


Location History:

  • Ho/ llviken, SE (1996)
  • 236 34 Hollviken, SE (1997)
  • Hollviken, SE (1999)
  • 35 Skanor, SE (2006)
  • Skanor, SE (2001 - 2014)

Company Filing History:


Years Active: 1996-2014

Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Hans Lilja

Introduction

Hans Lilja is a notable inventor based in Skanor, Sweden. He has made significant contributions to the field of therapeutic drugs, particularly through his innovative work on peptide prodrugs. With a total of 11 patents to his name, Lilja's inventions have the potential to greatly impact medical treatments.

Latest Patents

One of Hans Lilja's latest patents focuses on the "Activation of peptide prodrugs by hK2." This invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are designed to substantially inhibit the non-specific toxicity of various therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and can exert their intended toxicity. Additionally, methods for treating cell proliferative disorders are featured in this invention.

Career Highlights

Throughout his career, Hans Lilja has worked with prestigious institutions, including The Johns Hopkins University. His research and innovations have contributed to advancements in the medical field, particularly in drug development and treatment methodologies.

Collaborations

Hans Lilja has collaborated with notable individuals in his field, including John Tod Isaacs and Samuel Ray Denmeade. These collaborations have further enhanced the impact of his inventions and research.

Conclusion

Hans Lilja's innovative work in the field of peptide prodrugs showcases his dedication to improving therapeutic drug efficacy and safety. His contributions continue to influence medical research and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…